An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Eli Lilly, Novo Nordisk and other …
Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. The injectable weight loss medication Wegovy at New City Halstead Pharmacy in Chicago on April 24, 2024. Scott Olson | Getty Images Good morning! More U.S. employers are covering a buzzy class of …
My top 10 things to watch Wednesday, June 12 Stocks jumped after the May consumer price index came in cooler than Wall Street expected. Bonds yields fell after CPI, with the yield on the Fed-sensitive 2-year Treasury reaching its lowest level since April 5. The Dow , the S & …
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. AJ …
Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! I’m back in New York City after …
Alphabet incoming CFO Anat Ashkenazi, who spent 23 years at Eli Lilly Eli Lilly Alphabet’s outgoing finance chief, Ruth Porat, spent the past year and a half trying to help her internet company navigate the generative artificial intelligence boom. The person who was just named her successor was knee-deep in …
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Companies are increasing access to new blockbuster weight-loss drugs for employees, but size of employer may make a big difference in early access. Small businesses …
Patent protection for Wegovy — Novo Nordisk’s blockbuster weight loss drug, which contains the second generation GLP-1 active ingredient and is at least twice as effective — is expected to expire by the decade’s end. Michael Siluk | UCG | Getty Images For Gray Beard, a kindergarten teacher in Charlotte, …
Skynesher | E+ | Getty Images Big pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a “massive opportunity.” It’s called targeted radiopharmaceutical therapy. It essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule. RBC …
There’s been a lot of attention lately on a corner of the oncology market called radiopharmaceuticals. The therapy seeks to destroy cancer cells by binding a radioactive particle to a targeted molecule and then dispatching it directly into the tumor. There are currently two products on the market from Novartis …
